Proteomics-Based technologies in the discovery of biomarkers for multiple sclerosis in the cerebrospinal fluid

Current Molecular Medicine

Volumn 11, Issue 4, 2011, Pages 326-349

  Lourenco A S T ^a   Baldeiras, I ^b,c,d   Graos M ^a   Duarte, C B ^a,c,e  

^a Cell Biology Unit   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Biomarkers; Cerebrospinal fluid; Multiple sclerosis; Proteomics

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; ANGIOTENSINOGEN; APOLIPOPROTEIN A4; APOLIPOPROTEIN D; APOLIPOPROTEIN E; AUTOTAXIN; AUTOTAXIN T; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CHROMOGRANIN A; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4B; FETUIN A; FIBRINOGEN; FIBRINOGEN BETA CHAIN; HAPTOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN GAMMA 1 CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; PIGMENT EPITHELIUM DERIVED FACTOR; PREALBUMIN; PROSTAGLANDIN D SYNTHASE; RETINOL BINDING PROTEIN; SERINE PROTEINASE INHIBITOR; SPARC LIKE PROTEIN; TRANSFERRIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN METABOLISM; BRAIN TISSUE; CELL ADHESION; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CYTOSKELETON; DISCRIMINANT ANALYSIS; DISEASE MARKER; ELECTROSPRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLUORESCENCE ANALYSIS; HUMAN; IMMUNE SYSTEM; INTERMETHOD COMPARISON; LINEAR DISCRIMINANT ANALYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; TISSUE REGENERATION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

EID: 79958096423     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411795677981     Document Type: Article

References (208)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
2. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-8.
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
4. Tintore M. Rationale for early intervention with immunomodulatory treatments. J Neurol 2008; 255 Suppl 1: 37-43.
5. Poser CM, Brinar VV. The accuracy of prevalence rates of multiple sclerosis: a critical review. Neuroepidemiology 2007; 29: 150-5.
6. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463-78.
7. Romeo MJ, Espina V, Lowenthal M, et al. CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2005; 2: 57-70.
8. Wagner HJ, Pilgrim C, Brandl J. Penetration and removal of horseradish peroxidase injected into the cerebrospinal fluid: role of cerebral perivascular spaces, endothelium and microglia. Acta Neuropathol 1974; 27: 299-315.
9. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 1985; 326: 47-63.
10. Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS. Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics 2010; 74: 371-88.
11. Thongboonkerd V, Ramström M, Bergquist J. Proteomics of Human Cerebrospinal Fluid. In: Proteomics of Human Body Fluids; Humana Press; 2007; Vol. 12: pp. 269-84.
12. Tumani H, Hartung HP, Hemmer B, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009; 35: 117-27.
13. Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815: 179-89.
14. Hammack BN, Fung KY, Hunsucker SW, et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004; 10: 245-60.
15. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-22.
16. Teunissen CE, Tumani HT, Bennett JL, et al. Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. Mult Scler 2010; 16: 129-32.
17. Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. Neurol Sci 2003; 24 Suppl 5: S265-7.
18. Lehmensiek V, Sussmuth SD, Tauscher G, et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007; 13: 840-9.
19. Qin Z, Qin Y, Liu S. Alteration of DBP Levels in CSF of Patients with MS by Proteomics Analysis. Cell Mol Neurobiol 2008; 29: 203-10.
20. D'Aguanno S, Barassi A, Lupisella S, et al. Differential cerebro spinal fluid proteome investigation of Leber hereditary optic neuropathy (LHON) and multiple sclerosis. J Neuroimmunol 2008; 193: 156-60.
21. Tumani H, Lehmensiek V, Rau D, et al. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett 2009; 452: 214-7.
22. Noben JP, Dumont D, Kwasnikowska N, et al. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 2006; 5: 1647-57.
23. Chiasserini D, Di Filippo M, Candeliere A, et al. CSF proteome analysis in multiple sclerosis patients by twodimensional electrophoresis. Eur J Neurol 2008; 15: 998-1001.
24. Mattsson N, Ruetschi U, Podust VN, et al. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 2007; 103: 1932-9.
25. Ottervald J, Franzen B, Nilsson K, et al. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010; 73: 1117-32.
26. Liu S, Bai S, Qin Z, et al. Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J Cell Mol Med 2009; 13: 1586-603.
27. Stoop MP, Dekker LJ, Titulaer MK, et al. Multiple sclerosisrelated proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008; 8: 1576-85.
28. Stoop MP, Dekker LJ, Titulaer MK, et al. Quantitative matrixassisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 2009; 8: 1404-14.
29. Irani DN, Anderson C, Gundry R, et al. Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 2006; 59: 237-47.
30. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005; 4: 341-8.
31. Manadas BJ, Vougas K, Fountoulakis M, Duarte CB. Sample sonication after trichloroacetic acid precipitation increases protein recovery from cultured hippocampal neurons, and improves resolution and reproducibility in two-dimensional gel electrophoresis. Electrophoresis 2006; 27: 1825-31.
32. Yuan X, Desiderio DM. Proteomics analysis of prefractionated human lumbar cerebrospinal fluid. Proteomics 2005; 5: 541-50.
33. Tumani H, Lehmensiek V, Lehnert S, Otto M, Brettschneider J. 2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Rev Proteomics 2010; 7: 29-38.
34. Bjorhall K, Miliotis T, Davidsson P. Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005; 5: 307-17.
35. Ramstrom M, Zuberovic A, Gronwall C, et al. Development of affinity columns for the removal of high-abundance proteins in cerebrospinal fluid. Biotechnol Appl Biochem 2009; 52: 159-66.
36. Shores KS, Knapp DR. Assessment approach for evaluating high abundance protein depletion methods for cerebrospinal fluid (CSF) proteomic analysis. J Proteome Res 2007; 6: 3739-51.
37. Issaq HJ, Conrads TP, Janini GM, Veenstra TD. Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis 2002; 23: 3048-61.
38. Issaq HJ, Veenstra TD. The role of electrophoresis in disease biomarker discovery. Electrophoresis 2007; 28: 1980-8.
39. Manadas B, Santos AR, Szabadfi K, et al. BDNF-induced changes in the expression of the translation machinery in hippocampal neurons: protein levels and dendritic mRNA. J Proteome Res 2009; 8: 4536-52.
40. Sapra R. The use of difference in-gel electrophoresis for quantitation of protein expression. Methods Mol Biol 2009; 492: 93-112.
41. Issaq H, Veenstra T. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE): advances and perspectives. Biotechniques 2008; 44: 697-700.
42. Berven FS, Flikka K, Berle M, Vedeler C, Ulvik RJ. Proteomic-based biomarker discovery with emphasis on cerebrospinal fluid and multiple sclerosis. Curr Pharm Biotechnol 2006; 7: 147-58.
43. Rabilloud T, Strub JM, Luche S, van Dorsselaer A, Lunardi J. A comparison between Sypro Ruby and ruthenium II tris (bathophenanthroline disulfonate) as fluorescent stains for protein detection in gels. Proteomics 2001; 1: 699-704.
44. Wei X, Li L. Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases. Int J Clin Exp Pathol 2009; 2: 132-48.
45. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol Cell Biol 2004; 5: 699-711.
46. Glish GL, Vachet RW. The basics of mass spectrometry in the twenty-first century. Nat Rev Drug Discov 2003; 2: 140-50.
47. Ahmed FE. Utility of mass spectrometry for proteome analysis: part I. Conceptual and experimental approaches. Expert Rev Proteomics 2008; 5: 841-64.
48. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003; 49: 1041-4.
49. Rosengren AT, Salmi JM, Aittokallio T, et al. Comparison of PDQuest and Progenesis software packages in the analysis of two-dimensional electrophoresis gels. Proteomics 2003; 3: 1936-46.
50. Marengo E, Robotti E, Antonucci F, et al. Numerical approaches for quantitative analysis of two-dimensional maps: a review of commercial software and home-made systems. Proteomics 2005; 5: 654-66.
51. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004; 4: 3665-85.
52. Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Paez de la Cadena M. Improvements in the search for potential biomarkers by proteomics: application of principal component and discriminant analyses for two-dimensional maps evaluation. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 849: 251-60.
53. Zhu W, Smith JW, Huang CM. Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol 2010; 2010: 840518.
54. Marengo E, Robotti E, Bobba M. 2D-PAGE maps analysis. Methods Mol Biol 2008; 428: 291-325.
55. Jacobsen S, Grove H, Jensen KN, et al. Multivariate analysis of 2-DE protein patterns-practical approaches. Electrophoresis 2007; 28: 1289-99.
56. Marengo E, Robotti E, Bobba M, et al. Multivariate statistical tools applied to the characterization of the proteomic profiles of two human lymphoma cell lines by two-dimensional gel electrophoresis. Electrophoresis 2006; 27: 484-94.
57. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008; 14: 5967-76.
58. Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006; 38: 317-23.
59. Bjerre M, Hansen TK, Flyvbjerg A, Tonnesen E. Simultaneous detection of porcine cytokines by multiplex analysis: Development of magnetic bioplex assay. Vet Immunol Immunopathol 2009; 130: 53-8.
60. Kerr JR, Barah F, Chiswick ML, et al. Evidence for the role of demyelination, HLA-DR alleles, and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J Neurol Neurosurg Psychiatry 2002; 73: 739-46.
61. Kim K, Kim Y. Preparing multiple-reaction monitoring for quantitative clinical proteomics. Expert Rev Proteomics 2009; 6: 225-9.
62. Lescuyer P. How Shall We Use the Proteomics Toolbox for Biomarker Discovery? J Proteome Res 2007; 6: 3371-6.
63. Dieterle F. New technologies around biomarkers and their interplay with drug development. Anal Bioanal Chem 2007; 390: 141-54.
64. Lutterotti A, Berger T, Reindl M. Biological markers for multiple sclerosis. Curr Med Chem 2007; 14: 1956-65.
65. Fox RJ, Bethoux F, Goldman MD, Cohen JA. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med 2006; 73: 91-102.
66. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-69.
67. Huang D, Rae-Grant A. Advances in the immune pathogenesis and treatment of multiple sclerosis. Cent Nerv Syst Agents Med Chem 2009; 9: 20-31.
68. Ingram G, Hakobyan S, Robertson NP, Morgan BP. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol 2009; 155: 128-39.
69. Jans H, Heltberg A, Zeeberg I, et al. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Acta Neurol Scand 1984; 69: 34-8.
70. Jongen PJ, Doesburg WH, Ibrahim-Stappers JL, et al. Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 2000; 101: 116-21.
71. Bagnato F, Durastanti V, Finamore L, Volante G, Millefiorini E. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis. Neurol Sci 2003; 24 Suppl 5: S301-4.
72. Bagnato F, Zivadinov R, Cecchinelli D, et al. beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. Eur J Neurol 2004; 11: 455-60.
73. Beyne P, Lisovoski F, Got L, Ayache P, Delacoux E. Beta-2 microglobulin in cerebrospinal fluid in neurology. Presse Med 1995; 24: 1071-4.
74. Ott M, Demisch L, Engelhardt W, Fischer PA. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J Neurol 1993; 241: 108-14.
75. Bjerrum OW, Bach FW, Zeeberg I. Increased level of cerebrospinal fluid beta 2-microglobulin is related to neurologic impairment in multiple sclerosis. Acta Neurol Scand 1988; 78: 72-5.
76. Carrieri PB, Indaco A, Maiorino A, et al. Cerebrospinal fluid beta-2-microglobulin in multiple sclerosis and AIDS dementia complex. Neurol Res 1992; 14: 282-3.
77. Suzuki T, Tozuka M, Kazuyoshi Y, et al. Predominant apolipoprotein J exists as lipid-poor mixtures in cerebrospinal fluid. Ann Clin Lab Sci 2002; 32: 369-76.
78. Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev 2009; 61: 89-104.
79. Polihronis M, Paizis K, Carter G, Sedal L, Murphy B. Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. J Neurol Sci 1993; 115: 230-3.
80. Huang YC, Lyu RK, Tseng MY, et al. Decreased intrathecal synthesis of prostaglandin D2 synthase in the cerebrospinal fluid of patients with acute inflammatory demyelinating polyneuropathy. J Neuroimmunol 2009; 206: 100-5.
81. Kagitani-Shimono K, Mohri I, Oda H, et al. Lipocalin-type prostaglandin D synthase (beta-trace) is upregulated in the alphaB-crystallin-positive oligodendrocytes and astrocytes in the chronic multiple sclerosis. Neuropathol Appl Neurobiol 2006; 32: 64-73.
82. Melegos DN, Freedman MS, Diamandis EP. Prostaglandin D synthase concentration in cerebrospinal fluid and serum of patients with neurological disorders. Prostaglandins 1997; 54: 463-74.
83. Tseng CF, Lin CC, Huang HY, Liu HC, Mao SJ. Antioxidant role of human haptoglobin. Proteomics 2004; 4: 2221-8.
84. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42: 1589-600.
85. Wagner L, Gessl A, Parzer SB, et al. Haptoglobin phenotyping by newly developed monoclonal antibodies. Demonstration of haptoglobin uptake into peripheral blood neutrophils and monocytes. J Immunol 1996; 156: 1989-96.
86. Rosnowska M, Cendrowski W. Haptoglobin levels in the serum and the cerebrospinal fluid patients with multiple sclerosis. Neurol Neurochir Pol 1978; 12: 579-85.
87. van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006; 533: 319-26.
88. Fredrikson S. Clinical usefulness of cerebrospinal fluid evaluation. Int MS J 2010; 17: 24-7.
89. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006; 180: 17-28.
90. Gaillard O, Gervais A, Meillet D, et al. Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation. J Neurol Sci 1998; 158: 180-6.
91. Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell Biochem 2008; 49: 241-68.
92. Zhang HL, Wu J, Zhu J. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol 2010; 2010: 186813.
93. Rifai N, Christenson RH, Gelman BB, Silverman LM. Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination. Clin Chem 1987; 33: 1155-7.
94. Ramsaransing GS, Heersema DJ, De Keyser J. Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis. Eur J Neurol 2005; 12: 514-8.
95. Zhang HL, Wu J, Zhu J. The role of apolipoprotein E in Guillain-Barre syndrome and experimental autoimmune neuritis. J Biomed Biotechnol 2010; 2010: 357412.
96. Gelman BB, Rifai N, Christenson RH, Silverman LM. Cerebrospinal fluid and plasma apolipoproteins in patients with multiple sclerosis. Ann Clin Lab Sci 1988; 18: 46-52.
97. Korschenhausen DA, Hampel HJ, Ackenheil M, Penning R, Muller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 1996; 19: 103-9.
98. Adams RA, Schachtrup C, Davalos D, Tsigelny I, Akassoglou K. Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. Curr Med Chem 2007; 14: 2925-36.
99. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gcglobulin) and its polymorphism. Clin Chim Acta 2006; 372: 33-42.
100. Jensen PE, Humle Jorgensen S, Datta P, Sorensen PS. Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis. Biochim Biophys Acta 2004; 1690: 203-7.
101. Price P, Cuzner ML. Proteinase inhibitors in cerebrospinal fluid in multiple sclerosis. J Neurol Sci 1979; 42: 251-9.
102. Harris VK, Diamanduros A, Good P, et al. Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol Dis 40: 331-9.
103. Lebreton JP, Joisel F, Raoult JP, et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118-29.
104. Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993; 7: 1445-55.
105. Galembeck F, Cann JR. Fetuin as a trypsin inhibitor. Arch Biochem Biophys 1974; 164: 326-31.
106. Ashida H, Yamamoto K, Kumagai H. Trypsin inhibitory activity of bovine fetuin de-O-glycosylated by endo-alpha-Nacetylgalactosaminidase. Biosci Biotechnol Biochem 2000; 64: 2266-8.
107. Harris VK, Diamanduros A, Good P, et al. Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol Dis 2010; 40: 331-9.
108. Scarisbrick IA, Blaber SI, Lucchinetti CF, et al. Activity of a newly identified serine protease in CNS demyelination. Brain 2002; 125: 1283-96.
109. Prapunpoj P, Leelawatwattana L. Evolutionary changes to transthyretin: structure-function relationships. FEBS J 2009; 276: 5330-41.
110. D'Aguanno S, Franciotta D, Lupisella S, et al. Protein profiling of Guillain-Barre syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry. Neurosci Lett 2010; 485: 49-54.
111. Lamoureux G, Jolicoeur R, Giard N, St-Hilaire M, Duplantis F. Cerebrospinal fluid proteins in multiple sclerosis. Neurology 1975; 25: 537-46.
112. Larsen PD, DeLallo LJ. Cerebrospinal fluid transthyretin in multiple sclerosis. Neurology 1987; 37: 1262-3.
113. Krzalic L. Prealbumin content of cerebrospinal fluid and sera in persons with multiple sclerosis. Clin Chim Acta 1982; 124: 339-41.
114. Hulet SW, Powers S, Connor JR. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J Neurol Sci 1999; 165: 48-55.
115. Zeman D, Adam P, Kalistova H, et al. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients. Acta Neurol Scand 2000; 101: 89-94.
116. Sfagos C, Makis AC, Chaidos A, et al. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler 2005; 11: 272-5.
117. Levine SM, Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci 2004; 1012: 252-66.
118. LeVine SM, Lynch SG, Ou CN, et al. Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res 1999; 821: 511-5.
119. Rassart E, Bedirian A, Do Carmo S, et al. Apolipoprotein D. Biochim Biophys Acta 2000; 1482: 185-98.
120. Reindl M, Knipping G, Wicher I, et al. Increased intrathecal production of apolipoprotein D in multiple sclerosis. J Neuroimmunol 2001; 119: 327-32.
121. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J 2000; 348 Pt 3: 481-95.
122. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 1998; 274: H1836-40.
123. Shen L, Pearson KJ, Xiong Y, et al. Characterization of apolipoprotein A-IV in brain areas involved in energy homeostasis. Physiol Behav 2008; 95: 161-7.
124. Weimer JM, Stanco A, Cheng JG, et al. A BAC transgenic mouse model to analyze the function of astroglial SPARCL1 (SC1) in the central nervous system. Glia 2008; 56: 935-41.
125. Gongidi V, Ring C, Moody M, et al. SPARC-like 1 regulates the terminal phase of radial glia-guided migration in the cerebral cortex. Neuron 2004; 41: 57-69.
126. Lively S, Brown IR. Analysis of the extracellular matrix protein SC1 during reactive gliosis in the rat lithiumpilocarpine seizure model. Brain Res 2007; 1163: 1-9.
127. McKinnon PJ, Margolskee RF. SC1: a marker for astrocytes in the adult rodent brain is upregulated during reactive astrocytosis. Brain Res 1996; 709: 27-36.
128. Mendis DB, Ivy GO, Brown IR. SC1, a brain extracellular matrix glycoprotein related to SPARC and follistatin, is expressed by rat cerebellar astrocytes following injury and during development. Brain Res 1996; 730: 95-106.
129. Mendis DB, Shahin S, Gurd JW, Brown IR. SC1, a SPARCrelated glycoprotein, exhibits features of an ECM component in the developing and adult brain. Brain Res 1996; 713: 53-63.
130. Yan Q, Sage EH. SPARC, a matricellular glycoprotein with important biological functions. J Histochem Cytochem 1999; 47: 1495-506.
131. Boutin JA, Ferry G. Autotaxin. Cell Mol Life Sci 2009; 66: 3009-21.
132. Ye X, Fukushima N, Kingsbury MA, Chun J. Lysophosphatidic acid in neural signaling. Neuroreport 2002; 13: 2169-75.
133. Nakamura K, Ohkawa R, Okubo S, et al. Autotaxin enzyme immunoassay in human cerebrospinal fluid samples. Clin Chim Acta 2009; 405: 160-2.
134. Sato K, Malchinkhuu E, Muraki T, et al. Identification of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fluid and its possible sources. J Neurochem 2005; 92: 904-14.
135. Kawaguchi T, Yamagishi SI, Sata M. Structure-function relationships of PEDF. Curr Mol Med 2010; 10: 302-11.
136. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003; 4: 628-36.
137. McKinley MJ, Albiston AL, Allen AM, et al. The brain reninangiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003; 35: 901-18.
138. Savaskan E. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res 2005; 2: 29-35.
139. Wosik K, Cayrol R, Dodelet-Devillers A, et al. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007; 27: 9032-42.
140. Lloyd RV, Cano M, Rosa P, Hille A, Huttner WB. Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors. Am J Pathol 1988; 130: 296-304.
141. Ulrich G, Ciesielski-Treska J, Taupenot L, Bader MF. Chromogranin A-activated microglial cells induce neuronal apoptosis. Ann N Y Acad Sci 2002; 971: 560-2.
142. Eder U, Leitner B, Kirchmair R, et al. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J Neural Transm 1998; 105: 39-51.
143. Napolioni V, Moavero R, Curatolo P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain Dev 2009; 31: 104-13.
144. Orlova KA, Crino PB. The tuberous sclerosis complex. Ann N Y Acad Sci 2010; 1184: 87-105.
145. Yamamoto-Watanabe Y, Watanabe M, Jackson M, et al. Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. Brain Res 2010.
146. Grzonka Z, Jankowska E, Kasprzykowski F, et al. Structural studies of cysteine proteases and their inhibitors. Acta Biochim Pol 2001; 48: 1-20.
147. Tizon B, Sahoo S, Yu H, et al. Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS One 2010; 5: e9819.
148. Tizon B, Ribe EM, Mi W, Troy CM, Levy E. Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis 2010; 19: 885-94.
149. Bollengier F. Cystatin C, alias post-gamma-globulin: a marker for multiple sclerosis? J Clin Chem Clin Biochem 1987; 25: 589-93.
150. Nakashima I, Fujinoki M, Fujihara K, et al. Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann Neurol 2007; 62: 197-200.
151. Nagai A, Terashima M, Harada T, et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta 2003; 329: 53-60.
152. Hansson SF, Simonsen AH, Zetterberg H, et al. Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol 2007; 62: 193-6; discussion 205.
153. Walshe JM. Diagnostic significance of reduced serum caeruloplasmin concentration in neurological disease. Mov Disord 2005; 20: 1658-61.
154. Capo CR, Arciello M, Squitti R, et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 2008; 21: 367-72.
155. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 2005; 49: 633-40.
156. Texel SJ, Xu X, Harris ZL. Ceruloplasmin in neurodegenerative diseases. Biochem Soc Trans 2008; 36: 1277-81.
157. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry 2005; 76: 1046-57.
158. Zagorski T, Dudek I, Berkan L, et al. Superoxide dismutase (SOD-1) activity in erythrocytes of patients with multiple sclerosis. Neurol Neurochir Pol 1991; 25: 725-30.
159. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41.
160. Odell AF, Van Helden DF, Scott JL. The spectrin cytoskeleton influences the surface expression and activation of human transient receptor potential channel 4 channels. J Biol Chem 2008; 283: 4395-407.
161. Hirakawa S, Oohashi T, Su WD, et al. The brain link protein-1 (BRAL1): cDNA cloning, genomic structure, and characterization as a novel link protein expressed in adult brain. Biochem Biophys Res Commun 2000; 276: 982-9.
162. Steck E, Braun J, Pelttari K, et al. Chondrocyte secreted CRTAC1: a glycosylated extracellular matrix molecule of human articular cartilage. Matrix Biol 2007; 26: 30-41.
163. Aspberg A, Adam S, Kostka G, Timpl R, Heinegard D. Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem 1999; 274: 20444-9.
164. Rauch U, Zhou XH, Roos G. Extracellular matrix alterations in brains lacking four of its components. Biochem Biophys Res Commun 2005; 328: 608-17.
165. de Vega S, Iwamoto T, Yamada Y. Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 2009; 66: 1890-902.
166. Rindler MJ, Xu CF, Gumper I, et al. Calsyntenins are secretory granule proteins in anterior pituitary gland and pancreatic islet alpha cells. J Histochem Cytochem 2008; 56: 381-8.
167. Hintsch G, Zurlinden A, Meskenaite V, et al. The calsyntenins-a family of postsynaptic membrane proteins with distinct neuronal expression patterns. Mol Cell Neurosci 2002; 21: 393-409.
168. Cheng XR, Zhou WX, Zhang YX. The family of calsyntenins: learning and memory related genes. Sheng Li Ke Xue Jin Zhan 2006; 37: 205-10.
169. Nakahara J, Kanekura K, Nawa M, Aiso S, Suzuki N. Abnormal expression of TIP30 and arrested nucleocytoplasmic transport within oligodendrocyte precursor cells in multiple sclerosis. J Clin Invest 2009; 119: 169-81.
170. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 2002; 33: 774-97.
171. Guo TB, Boros LG, Chan KC, et al. Spermatogenetic expression of RNA-binding motif protein 7, a protein that interacts with splicing factors. J Androl 2003; 24: 204-14.
172. Dey P, Islam A, Ahmad F, Batra JK. Role of unique basic residues of human pancreatic ribonuclease in its catalysis and structural stability. Biochem Biophys Res Commun 2007; 360: 809-14.
173. Seidel B, Dong W, Savaria D, et al. Neuroendocrine protein 7B2 is essential for proteolytic conversion and activation of proprotein convertase 2 in vivo. DNA Cell Biol 1998; 17: 1017-29.
174. Sato A, Matsumoto A, Yamamoto T, Tanaka S, Suzuki H. Distribution of 7B2 (secretogranin V)-like immunoreactivity in the Japanese red-bellied newt (Cynops pyrrhogaster) pituitary. Tissue Cell 2010; 42: 176-80.
175. Mbikay M, Seidah NG, Chretien M. Neuroendocrine secretory protein 7B2: structure, expression and functions. Biochem J 2001; 357: 329-42.
176. McCombe PA, Clark P, Frith JA, et al. Alpha-1 antitrypsin phenotypes in demyelinating disease: an association between demyelinating disease and the allele PiM3. Ann Neurol 1985; 18: 514-6.
177. Pearl GS, Mullins RE. Alpha 1-antitrypsin in cerebrospinal fluid of patients with neurologic diseases. Arch Neurol 1985; 42: 775-7.
178. Abraham CR, Potter H. The protease inhibitor, alpha 1-antichymotrypsin, is a component of the brain amyloid deposits in normal aging and Alzheimer's disease. Ann Med 1989; 21: 77-81.
179. Zhang S, Janciauskiene S. Multi-functional capability of proteins: alpha1-antichymotrypsin and the correlation with Alzheimer's disease. J Alzheimers Dis 2002; 4: 115-22.
180. Gomis-Ruth FX, Bayes A, Sotiropoulou G, et al. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J Biol Chem 2002; 277: 27273-81.
181. Okui A, Kominami K, Uemura H, Mitsui S, Yamaguchi N. Characterization of a brain-related serine protease, neurosin (human kaillikrein 6), in human cerebrospinal fluid. Neuroreport 2001; 12: 1345-50.
182. Blaber SI, Ciric B, Christophi GP, et al. Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J 2004; 18: 920-2.
183. Scarisbrick IA, Linbo R, Vandell AG, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 2008; 389: 739-45.
184. Vukovic J, Marmorstein LY, McLaughlin PJ, et al. Lack of fibulin-3 alters regenerative tissue responses in the primary olfactory pathway. Matrix Biol 2009; 28: 406-15.
185. Petersen TE, Martzen MR, Ichinose A, Davie EW. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990; 265: 6104-11.
186. Santos AR, Comprido D, Duarte CB. Regulation of local translation at the synapse by BDNF. Prog Neurobiol 92: 505-16.
187. Carvalho AL, Caldeira MV, Santos SD, Duarte CB. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol 2008; 153 Suppl 1: S310-24.
188. Bollengier F, Mahler A, Clinet G, Delmotte P. Measles antibodies, anti-proteinase and plasminogen distribution in serum and plasma from patients affected with multiple sclerosis and patients affected with non-neurological diseases. J Clin Chem Clin Biochem 1984; 22: 653-9.
189. Kalaria RN, Golde T, Kroon SN, Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer's disease. Am J Pathol 1993; 143: 886-93.
190. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001; 86: 51-6.
191. Beilin O, Karussis DM, Korczyn AD, et al. Increased thrombin inhibition in experimental autoimmune encephalomyelitis. J Neurosci Res 2005; 79: 351-9.
192. Ftouh S, Akbar MT, Hirsch SR, de Belleroche JS. Downregulation of Dickkopf 3, a regulator of the Wnt signalling pathway, in elderly schizophrenic subjects. J Neurochem 2005; 94: 520-30.
193. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998; 14: 59-88.
194. Dodds DC, Omeis IA, Cushman SJ, Helms JA, Perin MS. Neuronal pentraxin receptor, a novel putative integral membrane pentraxin that interacts with neuronal pentraxin 1 and 2 and taipoxin-associated calcium-binding protein 49. J Biol Chem 1997; 272: 21488-94.
195. Kirkpatrick LL, Matzuk MM, Dodds DC, Perin MS. Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2. J Biol Chem 2000; 275: 17786-92.
196. Sia GM, Beique JC, Rumbaugh G, et al. Interaction of the Nterminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron 2007; 55: 87-102.
197. Santos SD, Carvalho AL, Caldeira MV, Duarte CB. Regulation of AMPA receptors and synaptic plasticity. Neuroscience 2009; 158: 105-25.
198. Stoevring B, Jaliashvili I, Thougaard AV, et al. Tetranectin in cerebrospinal fluid of patients with multiple sclerosis. Scand J Clin Lab Invest 2006; 66: 577-83.
199. Tasheva ES, Koester A, Paulsen AQ, et al. Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities. Mol Vis 2002; 8: 407-15.
200. Madisen L, Neubauer M, Plowman G, et al. Molecular cloning of a novel bone-forming compound: osteoinductive factor. DNA Cell Biol 1990; 9: 303-9.
201. Ma QY, Zuo CL, Ma JH, et al. Glucocorticoid up-regulates mimecan expression in corticotroph cells. Mol Cell Endocrinol 2010; 321: 239-44.
202. Galperin MY, Koonin EV. 'Conserved hypothetical' proteins: prioritization of targets for experimental study. Nucleic Acids Res 2004; 32: 5452-63.
203. Ishioka N, Takahashi N, Putnam FW. Amino acid sequence of human plasma alpha 1B-glycoprotein: homology to the immunoglobulin supergene family. Proc Natl Acad Sci U S A 1986; 83: 2363-7.
204. Sun D, Zhao YY, Dai SP, et al. Cloning and analysis of human alpha-1B glycoprotein precursor gene: a novel member of human immunoglobulin superfamily. Yi Chuan Xue Bao 2002; 29: 299-302.
205. Delker SL, West AP, Jr., McDermott L, Kennedy MW, Bjorkman PJ. Crystallographic studies of ligand binding by Zn-alpha2-glycoprotein. J Struct Biol 2004; 148: 205-13.
206. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F. Zinc alpha 2-glycoprotein: a multidisciplinary protein. Mol Cancer Res 2008; 6: 892-906.
207. Tsachaki M, Ghiso J, Efthimiopoulos S. BRI2 as a central protein involved in neurodegeneration. Biotechnol J 2008; 3: 1548-54.
208. Berger T, Reindl M. Multiple sclerosis: disease biomarkers as indicated by pathophysiology. J Neurol Sci 2007; 259: 21-6.